OC
ZNTL icon

Oppenheimer & Co’s Zentalis Pharmaceuticals ZNTL Stock Holding History

Oppenheimer & Co’s Portfolio ZNTL Stock Details ZNTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$61.4K Buy
+12,656
New +$50.5K ﹤0.01% 1734

Other funds holding ZNTL

5VM
5AM Venture Management San Francisco, California $288M AUM 313.93% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SCM
Squadron Capital Management Westmont, Illinois $322M AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $1.1B AUM 197.64% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

Oppenheimer & Co's ZNTL Position: Q2 2026 in Review

Oppenheimer & Co opened a new position in Zentalis Pharmaceuticals (ZNTL) in Q2 2026: 12,656 shares worth $61.4K. The stake represents ﹤0.01% of the portfolio and ranks #1734 among its holdings.

114 funds tracked by Wall St. Rank hold ZNTL as of Q2 2026.

  • Oppenheimer & Co held 12,656 shares of Zentalis Pharmaceuticals worth $61.4K as of Q2 2026.
  • Zentalis Pharmaceuticals was a new Oppenheimer & Co position in Q2 2026.
  • Zentalis Pharmaceuticals made up ﹤0.01% of Oppenheimer & Co's portfolio in Q2 2026, its #1734 holding.
  • 114 funds tracked by Wall St. Rank held Zentalis Pharmaceuticals as of Q2 2026.

Based on Oppenheimer & Co's 13F filing for Q2 2026, filed 3 Aug 2026.